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1. Introduction 
The risk of lymphoma in inflammatory bowel disease (IBD) has been a topic of great interest 
for many years. In 1928, the first published series of colorectal malignancies in ulcerative 
colitis (UC) patients included a case of lymphosarcoma, the name given to an early 
classification of lymphoma (Bargen, 1928). Since then a huge number of case reports, case 
series, cohort studies, population-based studies and meta-analyses have been presented on 
the topic but the matter remains controversial with conflicting results based on poor quality 
evidence. Most recently, a type of non-Hodgkin’s lymphoma (NHL) known as 
hepatosplenic T-cell lymphoma (HSTCL) has understandably drawn much attention despite 
its rarity. HSTCL has an invariably fatal outcome despite reports of early response to 
treatment, it almost exclusively affects young men with Crohn’s disease (CD) and seems to 
be linked to commonly used drugs for the management of IBD, the thiopurines and tumour 
necrosis factor (TNF) antagonists (Kotlyar et al., 2011). A further source of concern stems 
from a trend by IBD physicians to use these drugs earlier in the course of disease and also in 
combination because recent studies suggest that these strategies may improve outcomes 
(Colombel et al., 2010, D'Haens, 2009). 
Proving causality has been difficult because it is difficult to separate the multiple factors 
involved in lymphomagenesis using the evidence that is available (see Figure 1). It has long 
been suspected that the chronic inflammation seen in IBD itself may be the cause of 
lymphoma in this setting but there has been growing concern that it is in fact the drugs used 
in the treatment of IBD which confers this risk. One could also speculate that it is the 
combination of both these factors which results in the development of lymphoma. 
The case of lymphosarcoma identified by Bargen in 1928 was in an era when 
immunomodulators were not available for the treatment of IBD suggesting that the disease 
itself may predispose to lymphoma development. There are other reports of lymphoma in 
drug-naïve IBD patients (Aydogan et al., 2010). There does appear to be an increased risk of 
lymphoma in other chronic inflammatory and autoimmune conditions as well including 
rheumatoid arthritis (RA), primary Sjögren’s syndrome, systemic lupus erythematosus 
(SLE) and Hashimoto’s thyroiditis (Smedby et al., 2006). There is some evidence that 
increased severity of the disease may increase the risk of lymphoma in these conditions 
(Baecklund et al., 2006, Theander et al., 2006, Lofstrom et al., 2007).  
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Fig. 1. Assessing the causality of lymphoma in IBD. IBD itself may be the cause of 
lymphoma (a), or lymphoma may be due to the medication used to treat it (b) or lymphoma 
may be due to a combination of the disease and the treatment (c). 
Both primary and acquired immunodeficiency states have been associated with lymphoma 
which is important because many of the drugs used for the treatment of IBD have 
immunosuppressive effects. There is an increased risk of lymphoma with Human 
Immunodeficiency Virus (HIV) infection and in post-transplant patients treated with 
immunosuppressives (Serraino et al., 1992, Grulich et al., 2007b). The role of Epstein-Barr 
virus (EBV) is well established in lymphomagenesis in post-transplant patients and this also 
appears to be important in IBD patients (Dayharsh et al., 2002). 
IBD is associated with significant morbidity and a small mortality (Rubin et al., 2004, Ghosh 
and Mitchell, 2007). It is important that IBD physicians are able to help patients weigh up 
the risk of lymphoma with the benefits of drugs used to treat IBD. A number of attempts 
have been made to quantify this risk. One of the largest population-based studies utilised a 
primary care database from the United Kingdom but did not find a statistically significant 
increased background risk of lymphoma in IBD patients (Lewis et al., 2001). A cohort study 
from Dublin found an alarmingly higher rate of lymphoma in their IBD patients with up to 
a 59-fold increase (Farrell et al., 2000). Kandiel et al performed a meta-analysis of 6 studies to 
evaluate the risk of lymphoma in IBD patients treated with thiopurines and found a 4-fold 
increased risk of lymphoma in these patients (Kandiel et al., 2005). 
A number of more recent studies have been presented in the literature including large 
cohort studies from the United States (US) and Spain (Chiorean et al., 2010, Van 
Domselaar et al., 2010) as well as large population-based studies from the UK and the 
Netherlands (Armstrong et al., 2010, Vos et al., 2010). Most notably, the French CESAME 
study published in 2009 with almost 50,000 patient-years of follow up, set out to quantify 
the risk of lymphoma and made attempts to distinguish the background risk of 
lymphoma due to IBD itself from the risk conferred by its treatment (Beaugerie et al., 
2009a). 
This chapter aims to provide an up to date systematic review of the available literature 
regarding the risk of lymphoma in inflammatory bowel disease. Meta-analysis techniques 
have been used to pool data from multiple studies. 
2. Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is a chronic, idiopathic, remitting and relapsing disorder 
of the gastrointestinal tract. It comprises of two main disease types, ulcerative colitis (UC) 
and Crohn’s disease (CD), which have many similar but also certain distinct pathological 
and clinical characteristics. 
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2.1 Epidemiology 
IBD affects 400 per 100,000 population in the United Kingdom but there is considerable 
variation worldwide with the highest prevalence in developed countries (Rubin et al., 2000). 
It most commonly presents in teenage or young adult life but it can affect any age and there 
is an approximate equal sex distribution. 
2.2 Aetiology 
The aetiology is unknown but evidence suggests an immune dysfunction which is triggered 
by an environmental factor in a genetically susceptible individual (Cho, 2008) leading to 
chronic inflammation and injury to the gastrointestinal tract. Many of the susceptibility 
genes identified in recent studies have been shown to have important roles in immune 
regulation but there is increasing evidence that these genes pertain to the innate immune 
system and are involved in the sensing or intracellular processing of bacteria (Packey and 
Sartor, 2008). Potential microbial triggers which have been studied include a form of 
enteroadherent Escherichia coli and Mycobacterium paratuberculosis, but more recent 
investigation suggests that a disturbance of normal enteric microflora may play a role in 
aetiology (Sartor, 2008). Additionally, a number of other potential environmental factors 
have also been studied including diet, smoking, appendiceal inflammation, certain drugs 
and stress but causality has remained difficult to establish (Bernstein, 2010). The particular 
combination of susceptible genes and environmental triggers probably varies between 
individuals with IBD and leads to different patterns and severity of disease.  
Ulcerative colitis causes a continuous mucosal inflammation of the colorectum, whereas 
Crohn’s disease can affect any part of the GI tract, characteristically with skip lesions and 
transmural inflammation. Additionally, chronic inflammation in Crohn’s disease can lead to 
fistulising and stricturing disease behaviours (Satsangi et al., 2006). 
2.3 Treatment 
A curative treatment for inflammatory bowel disease is yet to be identified. Strategies for the 
management of IBD involve treatment of flares and maintenance of remission. Although a 
wide range of therapies including enteral nutrition (Zachos et al., 2007), antibiotics (Lal and 
Steinhart, 2006) and complementary medicines (Langmead and Rampton, 2006) are used in 
IBD, the mainstay of treatment has been with anti-inflammatory and immunomodulatory 
drugs. Corticosteroids, 5-aminosalicylates (5ASA), azathioprine (AZA), mercaptopurine 
(6MP), methotrexate (MTX) and cyclosporin A (CSA) have been the most commonly used 
drugs. In an attempt to reduce steroid exposure and maintain remission, 
immunomodulatory therapy is being used earlier, for prolonged periods and in 
combination. The concern is of an increased risk of side effects with this approach. Estimates 
suggest that up to 30% of patients may not respond to this treatment and may require more 
aggressive strategies. The increased understanding of the pathogenesis of IBD, has led to 
investigation in to a number of therapies targeted towards the abnormal cytokine expression 
seen in patients with IBD. Of these, only the monoclonal antibodies against tumour necrosis 
factor are currently in clinical use but other targets have been identified and are undergoing 
laboratory and clinical study. Infliximab (IXB) and adalimumab (ADA) are the two anti-
tumour necrosis factor (anti-TNF) drugs available in the United Kingdom and a number of 
www.intechopen.com
 New Advances in the Basic and Clinical Gastroenterology 314 
studies have proven their efficacy (Hanauer et al., 2006, Hanauer et al., 2002, Jarnerot et al., 
2005). A third, pegylated anti-TNF drug, certolizumab has also been studied and appears to 
have equivalent clinical efficacy (Sandborn et al., 2007a). Despite medical therapy, up to 50-
70% of patients with CD will undergo surgery within 5 years of diagnosis and UC patients 
have a 20-30% lifetime risk of colectomy (Cosnes et al., 2005). 
2.4 Cancer risk in IBD 
The increased risk of colonic adenocarcinoma in patients with ulcerative colitis and Crohn’s 
colitis is well documented (Rutter et al., 2006, Jess et al., 2006). One study has suggested a 
protective role for thiopurines in this context (Beaugerie et al., 2009b) though these patients 
were not corrected for co-administration of 5ASA preparations which may also have a 
protective role in this setting. 
There also appears to be an increased risk of certain non-colorectal malignancies amongst 
IBD patients. In the same cohort of patients from the CESAME study, prospective data 
suggested a 20-fold increased risk of small bowel adenocarcinoma and suggestion of an 
increased risk of skin and cervical malignancy (Beaugerie et al., 2009c). In a database of over 
27,000 UC patients from Sweden, the standardised incidence ratio (SIR) for all cancers was 
1.46 with increased risk of malignancy of the liver, small bowel (carcinoid), prostate and 
breast (Hemminki et al., 2008). In a recent review of malignancies associated with thiopurine 
therapy, Smith et al concluded that these drugs did not increase the risk of cervical 
dysplasia, colonic cancer or solid organ tumours in IBD patients (Smith et al., 2010). A 
retrospective cohort study of over 50,000 IBD patients from the US suggested an increased 
risk of non-melanomatous skin cancer and that this risk was highest in patients treated with 
thiopurines (Odds Ratio 4.27) and biological therapies (Odds Ratio 2.18) (Long et al., 2010). 
Many of these studies have also shown an increased risk of lymphoma and this will be 
discussed further in this chapter. 
3. Lymphoma 
Lymphoma is a broad term used to describe a variety of neoplasms due to proliferation of 
lymphoid cells. Traditionally, lymphoid neoplasms that presented with bone marrow and 
blood involvement were referred to by the term leukaemia and those that presented with a 
mass would be called a lymphoma. However, it is now appreciated that any lymphoma can 
present with or evolve in to a leukaemic picture and occasionally, leukaemia can present with 
a mass lesion. 
3.1 Classification of lymphoma 
The earliest classifications of lymphoma were based entirely on the morphological features 
of the neoplastic cells involved. Historically, lymphomas represented by large cells were 
known as reticulosarcomas and those by small cells were lymphosarcomas (Diebold, 2001). 
Later, lymphomas began to be distinguished according to their origin from B or T 
lymphocytes. With the development of immunophenotyping and cytogenetics, as well as an 
appreciation of differences in prognosis and patient stratification, more complex 
classification systems have developed. The World Health Organisation (WHO) 
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Classification of Tumours of Haemopoietic and Lymphoid Tissues, updated in 2008 (see 
Table 1), is now widely accepted (Swerdlow et al., 2008) and categorises lymphoid 
neoplasms in to those derived from: 
 B cell progenitors - bone marrow derived 
 T cell progenitors - thymus derived 
 Mature T lymphocytes - cytotoxic or killer T cells, helper T cells or T regulatory cells 
 Mature B lymphocytes - B cells or plasma cells 
 
Non-Hodgkin’s Lymphoma 
  
Precursor B-cell lymphomas Precursor T-cell and NK-cell lymphomas 
  
Precursor B-cell lymphoblastic lymphoma Precursor T-cell lymphoblastic lymphoma 
 Blastic NK-cell lymphoma 
Mature B-cell lymphomas  
 Mature T-cell and NK-cell lymphomas 
Small lymphocytic lymphoma  
Lymphoplasmacytic lymphoma T-cell prolymphocytic leukaemia 
Splenic marginal zone lymphoma T-cell large granular lymphocytic leukaemia 
Hairy cell leukaemia Aggressive NK-cell leukaemia 
Plasma cell neoplasms Adult T-cell lymphoma/leukaemia 
Extranodal marginal zone B-cell MALT 
lymphoma 
Extranodal NK-/T-cell lymphoma, nasal type 
Nodal marginal zone B-cell lymphoma Enteropathy-type T-cell lymphoma 
Follicular lymphoma (grades 1, 2, 3a and 3b) Hepatosplenic T-cell lymphoma 
Diffuse follicle centre lymphoma 
Subcutaneous panniculitis-like T-cell 
lymphoma 
Mantle cell lymphoma Mycosis fungoides 
Diffuse large B-cell lymphoma Peripheral T-cell lymphoma unspecified 
Mediastinal (thymic) large B-cell lymphoma Angioimmunoblastic T-cell lymphoma 
Intravascular large B-cell lymphoma Anaplastic large cell lymphoma 
Primary effusion lymphoma  
Burkitt lymphoma  
  
B-cell proliferations of uncertain malignant 
potential 
 
  
Lymphomatoid granulomatosis  
Post-transplant lymphoproliferative disorder  
  
www.intechopen.com
 New Advances in the Basic and Clinical Gastroenterology 316 
Hodgkin’s Lymphoma 
 
Classical Hodgkin's lymphoma 
 
Nodular sclerosis classical HL 
Mixed cellularity classical HL 
 
 
Lymphocyte rich classical HL 
Lymphocyte depleted classical HL 
 
Nodular lymphocyte predominant HL 
 
Table 1. WHO Classification of Non-Hodgkin’s and Hodgkin’s Lymphoma (Swerdlow et al, 
2008). (MALT – mucosa-associated lymphoid tissue; HL – Hodgkin’s Lymphoma; NK – 
Natural Killer). 
Hodgkin’s lymphoma (formerly known as Hodgkin’s disease) arises from B-cells of 
germinal or post-germinal centres of peripheral lymph nodes. It is pathologically and 
clinically distinct from other lymphoid neoplasia and generally has a good prognosis. 
Hodgkin’s lymphoma has a distinguishing cellular composition on biopsy of lymphomatous 
tissues with abundant inflammatory cells and only a minority of neoplastic cells, known as 
Reed-Sternberg cells. Reed-Sternberg cells are large, binucleated or multinucleated 
containing multiple eosinophilic nucleoli and have prominent cytoplasm. Hodgkin’s 
lymphoma (HL) is classified in to nodular lymphocyte predominant HL and classical HL, which 
is further subdivided in to nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-
depleted types (see Table 1). 
The term Non-Hodgkin’s lymphoma encompasses all other types of lymphoma. Although 
the WHO classification does not distinguish NHL on the basis of disease activity, it has 
classically been divided in to two subtypes: 
 High-grade NHL develops quickly and aggressively. 
 Low-grade or indolent NHL develops slowly and there may be no symptoms for many 
years. 
3.2 Non-Hodgkin’s lymphoma 
NHL can occur in children and adults but over two-thirds are diagnosed in people aged 
over 60 years. There is a male preponderance with a ratio of up to 1.5 in older age groups. 
NHL is the fifth most common cancer in the UK with over 10,000 people diagnosed with the 
condition in 2007 and an age-standardised rate of 14.2 per 100,000 population (Cancer-
Research-UK, 2011) (see Figure 2A). In the United States, the Surveillance Epidemiology & 
End Results (SEER) registry provides an age-standardised rate of 19.6 per 100,000 between 
2003 and 2007 (Altekruse et al., 2010). The incidence of NHL seems to be rising in the UK  
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Fig. 2. Figures adapted from Cancer Research UK 2011. A: Incidence of non-Hodgkin’s 
lymphoma by gender. B: Incidence of Hodgkin’s lymphoma by gender. C: Age standardised 
incidence rates for non-Hodgkin’s lymphoma. D: Age standardised incidence rates for 
Hodgkin’s lymphoma. 
with an increase of 35% during the 20 year interval between 1988 and 2007 (see Figure 2C). 
This trend seems to be reflected throughout the world. Mortality in the UK is estimated at 
6.9 per 100,000 from NHL and with improvements in treatment, it is estimated that over half 
of patients now survive for at least 10 years following diagnosis. Up to 15% of all extra-
nodal NHL presents in the GI tract (Newton et al., 1997). 
A number of risk factors for the development of NHL have been studied: 
 Infectious agents – It is thought that a proportion of the worldwide rise in incidence of 
NHL parallels, but is not completely explained by, the HIV epidemic. The risk of NHL 
in HIV and AIDS is well documented but only 3-5% of these patients will develop NHL 
(Serraino et al., 1992). Epstein-Barr virus has been linked to Burkitt’s lymphoma and 
post-transplant lymphoma (Epstein et al., 1964). Other infections associated with an 
increased risk of NHL include Helicobacter Pylori (Xue et al., 2001), Hepatitis C (Dal 
Maso and Franceschi, 2006) and Human T-cell Lymphotropic Virus (HTLV-1) (Parkin, 
2006). 
 Immunosuppression – The use of immunosuppression following organ transplant has 
been shown to increase the risk of NHL and in a significant proportion of these, EBV 
A B
C D
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infection has been implicated (Kawashima et al., 1994). A recent meta-analysis suggests 
an 8-fold increased risk of NHL in post-transplant patients (Grulich et al., 2007b). 
 Autoimmune conditions – Conditions such as autoimmune haemolytic anaemia, 
systemic lupus erythematosus and Sjögren’s syndrome, where there is a longstanding 
stimulation of the immune system have been shown to carry an increased risk of NHL 
but the exact mechanisms remain poorly understood (Ekstrom Smedby et al., 2008). 
Coeliac disease is associated with T-cell lymphoma and less frequently, B-cell 
lymphoma (Chandesris et al., 2010, Oruc et al., 2010). This risk can be reduced by 
treatment with a gluten-free diet (Silano et al., 2008). 
 Genetic susceptibility – The sibling or progeny of an affected individual has an 
approximate two-fold increased risk of developing NHL and there appears to be 
concordance in NHL subtype (Altieri et al., 2005). 
 Exposure to chemical carcinogens – A number of studies and meta-analyses suggest an 
increased risk of NHL in individuals with occupational exposure to agricultural 
pesticides (Merhi et al., 2007), benzene (Steinmaus et al., 2008) and aromatic 
hydrocarbons (Miligi et al., 2006). 
 Diet and obesity – Dietary factors and the risk of lymphoma are controversial. A recent 
study from Iowa found a 31% risk reduction for women with a higher intake of fruit 
and vegetables (Thompson et al., 2010). However, an earlier cohort study did not 
corroborate this finding (Zhang et al., 2000). NHL appears to be associated with obesity 
with one meta-analysis showing a relative risk of 1.4 for diffuse large B-cell NHL 
amongst individuals with a BMI ≥ 30 kg/m2 (Larsson and Wolk, 2007). 
3.3 Hodgkin’s lymphoma 
Hodgkin’s lymphoma represents 15% of all lymphomas and accounts for only 0.6% of all 
cancers diagnosed in the United Kingdom (Cancer-Research-UK, 2011). The age 
standardised incidence in 2007 was 2.6 per 100,000 population in the UK and 2.8 per 100,000 
in the USA (Altekruse et al., 2010) (see Figure 2B). In the UK, age-specific peaks in incidence 
occur in early adult life (for men at 30 to 34 years and women at 20 to 24 years old) and in 
later life (over 70 years). Unlike NHL, the incidence of Hodgkin’s lymphoma seems to have 
fallen in the 1970s and has plateaued since the 1980s (see Figure 2D). This may be explained 
by changes in classification of different types of lymphoma. With treatment, prognosis for 
Hodgkin’s lymphoma is good with around 78% of patients with HL diagnosed in 2007 in 
the UK predicted to survive for at least 10 years according to calculations by Cancer 
Research UK. The overall age-standardised survival rate for patients diagnosed with HL in 
England between 1996 and 1999 was 80% (Coleman, 1999). The Nodular Sclerosis subtype of 
classical HL is the commonest occurring in 60% of cases and is associated with younger age 
and more affluent populations. 
Many of the risk factors for Hodgkin’s lymphoma are similar to those of NHL but certain 
factors may be more important in the development of HL: 
 Genetic susceptibility – a family history of Hodgkin’s lymphoma appears to have a 
much more dramatic effect on risk when compared to NHL. Monozygotic twin studies 
suggest a 99-fold increased risk (Mack et al., 1995) and a first degree relative diagnosed 
with any haematological malignancy confers a two to three-fold increased risk (Chang 
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et al., 2005, Goldin et al., 2004). Studies from the USA suggest racial differences in 
susceptibility with lower risk in blacks than whites (Glaser, 1991). 
 Epstein-Barr virus – EBV infection has long been implicated in the development of 
Hodgkin’s lymphoma. EBV DNA can be found in 40% of cases with higher rates of 
association found in the paediatric population (Jarrett et al., 1996). EBV positivity is 
more commonly found in the Mixed Cellularity than the Nodular Sclerosis subtypes of 
classical HL. A previous history of infectious mononucleosis confers an increased risk 
of HL with an SIR of 3.49 in patients aged 15 to 34 years (Hjalgrim et al., 2000). 
 Previous non-Hodgkin’s lymphoma – Studies suggest that patients who have 
previously been treated for NHL are at increased risk of subsequently developing HL 
with a magnitude in the order of four- to twelve-fold (Travis et al., 1991, Travis et al., 
1993). 
4. Pathogenesis of lymphoma in IBD 
Lymphoma is a clonal expansion of B- and T- lymphocytes caused by the accumulation of a 
series of genetic mutations affecting proto-oncogenes and tumour suppressor genes. This 
results in dysregulated proliferation, evasion of immune surveillance mechanisms and 
inhibition of apoptosis (Jaffe et al., 2001). Significant progress has been made in to the 
understanding of these mechanisms at a molecular level. The activation of oncogenes by 
aberrant chromosomal translocations as well as the inactivation of tumour suppressor genes 
by chromosomal deletion or mutation are both important mechanisms of lymphomagenesis 
(Kuppers et al., 1999). Oncogenic viruses such as EBV and HTLV1 can also introduce foreign 
genetic sequences into the lymphocyte genome causing disruption of normal function (Neri 
et al., 1991). 
There are a number of genetic, environmental, infectious and iatrogenic factors amongst 
patients with inflammatory bowel disease which can predispose to increased susceptibility 
to these mechanisms for the development of lymphoma: 
 Chronic inflammation – The pathogenesis of IBD is not completely understood but 
aberrations in the innate and adaptive immune response to luminal antigens has been 
the focus of much research. It can be postulated that the dysregulation of these immune 
systems seen in the chronic inflammation associated with IBD may lead to antigen-
driven lymphocyte proliferation and a relatively unhindered risk of genetic and 
chromosomal deviations (Sokol and Beaugerie, 2009). Another possibility is that the 
combination of metabolites, cytokines and chemokines seen in the mucosa of IBD 
patients promotes mutagenesis in bystander cells. These theories may help to explain 
the increased risk of lymphoma seen in a variety of different auto-immune conditions 
and their concordance to sites of inflammation (Smedby et al., 2006). EBV related 
lymphoma has been reported in longstanding pyothorax of over 20 years duration 
(Aozasa et al., 2005). This is a condition which is regarded to be due to chronic 
suppuration with no autoimmunity and it is suggested that any chronic inflammatory 
state may predispose to lymphoma development. 
 Genetic susceptibility – Linkage studies and genome wide association studies have 
identified a large array of susceptibility genes for IBD (Barrett et al., 2008). These genetic 
changes may also be involved in the pathogenesis of lymphoma in certain individuals. 
For example, the first susceptibility gene identified, IBD1, encodes for the protein 
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NOD1 which in its wild-type activates nuclear factor kappa B (NF-κB) (Ogura et al., 
2001). NF-κB is a tightly regulated mediator of T- and B-lymphocytes and alterations in 
its signalling pathway have been implicated in a number of malignancies including 
lymphoma (Jost and Ruland, 2007). Although some plausibility exists, this link remains 
to be established. 
 Therapeutic immune modulation – Immunomodulatory drugs such as the thiopurines, 
(azathioprine and mercaptopurine), methotrexate, and the anti-TNF drugs (infliximab, 
adalimumab and certolizumab) have become standard treatment for complicated IBD. 
These drugs exert their effects through a number of mechanisms which are 
incompletely understood. It is recognised that AZA and its metabolites suppress 
intracellular inosinic acid synthesis which interferes with intracellular purine synthesis 
resulting in a down regulation of B- and T-cell proliferation (Bacon and Salmon, 1987). 
Thiopurine nucleotides also incorporate into lymphocyte DNA disrupting structure, 
repair mechanisms and promoting mutagenesis (Ling et al., 1992). There is also 
evidence that azathioprine renders DNA highly sensitive to damage to ultraviolet 
(UVA) radiation and this may account for the increased risk of non-melanomatous skin 
cancer in patients treated with thiopurines (O'Donovan et al., 2005). A recent study 
showed that IBD patients on thiopurine therapy had significantly more somatic 
mutations in circulating T-lymphocytes than in a thiopurine-naïve control group 
(Nguyen et al., 2009).  
The impact of anti-TNF drugs on the risk of mutagenesis has not been adequately 
studied. It is conceivable that interruption of TNF signalling disrupts immune 
surveillance mechanisms and alters the normal detection and elimination of cells with 
chromosomal abnormalities.  
At higher doses, methotrexate is cytotoxic, whereas the lower doses used in IBD 
patients are known to alter T-cell derived cytokines in inflammatory states. It inhibits 
pro-inflammatory cytokines such as interleukin-12, interferon-Ǆ and tumour necrosis 
factor-ǂ whilst promoting anti-inflammatory cytokines such as interleukin-10 (van 
Dieren et al., 2006). These cytokines have fundamental effects on lymphocyte 
proliferation and function but the specific mechanisms which may contribute to 
potential lymphoma development are not known. 
 Immunosuppression – The increased risk of lymphoma in patients with 
immunodeficiency states such as HIV infection (Serraino et al., 1992) and post-
transplant immunosuppression (Grulich et al., 2007a) is well recognised and many of 
these cases are EBV positive. The increased risk of opportunistic infections amongst IBD 
patients on immunomodulators therapy is also well documented. Toruner et al 
identified 100 cases of opportunistic infections over an 8 year period on their database 
of IBD patients from the Mayo Clinic and found that treatment with thiopurines 
conferred an Odds Ratio of 3.1 (Toruner et al., 2008). The majority of these opportunistic 
infections were caused by viruses including cytomegalovirus, Herpes simplex virus and 
Epstein-Barr virus. 
EBV is a widely disseminated human Herpes virus which has been associated with a 
number of different types of B-cell lymphoma, particularly mixed cellularity and 
lymphocyte depleted classical Hodgkin’s lymphoma, Burkitt’s lymphoma and post-
transplant lymphoproliferative disorder (PTLD). EBV viral load can predict risk of 
PTLD (Stevens et al., 2001) and cases of infectious mononucleosis with early 
transformation to lymphoma have been described (Owen et al., 2010). Interestingly, 
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Wong et al describe a case of synchronous colonic adenocarcinoma and lymphoma and 
demonstrated that EBV was present in the lymphomatous tissue but not in the invasive 
adenomatous tissue (Wong et al., 2003). A series of IBD patients from the Mayo clinic 
identified 12 patients diagnosed with lymphoma between 1993 and 2000, half of whom 
were on azathioprine therapy. The lymphomas of five out of these six patients on 
azathioprine were EBV positive whereas only one out of the six azathioprine-naïve 
patients was EBV positive (Dayharsh et al., 2002). This study suggests a link between 
azathioprine therapy and EBV driven lymphoma in IBD though the numbers were too 
small to reach statistical significance. In the CESAME prospective study of over 21,000 
French IBD patients, 9 of the 13 cases of lymphoma in patients on azathioprine were 
EBV positive with up to 16 years exposure to the drug (Beaugerie et al., 2009a). Reijasse 
et al measured EBV viral loads in patients with Crohn’s disease and EBV sero-positive 
controls. There was no difference in viral loads between the two groups irrespective of 
immunomodulator or biological therapy but a minority of patients did have transient, 
very high EBV viral loads (Reijasse et al., 2004). It is not clear, whether these peaks in 
EBV viral load are associated with lymphoma risk but this does appear to be the case in 
post-transplant patients where EBV viral load can predict this outcome (Stevens et al., 
2001). 
The pathobiology of EBV and its role in lymphomagenesis is complex. The host-
incorporated EBV genome encodes a number of proteins with similarities to a variety of 
cytokines, anti-apoptotic molecules and signal transducers that can immortalise and 
mutate infected cells (Sokol and Beaugerie, 2009). 
The risk of other oncogenic viruses such as HLTV1 is not well described in the IBD 
literature. A recent meta-analysis suggested a lower prevalence of Helicobacter Pylori 
infection in IBD patients compared to control groups but its association with gastric 
MALT-oma is well documented (Luther et al., 2010). 
5. Lymphoma risk in the literature 
In order to evaluate any causality between IBD and the risk of lymphoma, it is extremely 
important to appreciate the quality of safety data available. Frequently, this information is 
flawed and difficult to interpret. 
5.1 Quality of data 
Randomised controlled drug trials collate information regarding adverse events but they are 
powered to elucidate differences in efficacy and not safety. They also tend to have relatively 
small numbers and a short follow up period which may not reflect the true incidence of late 
or delayed adverse events. Some useful safety information is available from observational 
studies of large populations. These have large numbers and long follow up but are 
susceptible to indication bias and often have other confounding factors. Case controlled 
series have an efficient methodology but may be hampered by the shortcomings of control 
selection. The most common form of safety data comes from case reports and case series 
which are able to identify rare risks. However, the inherent positive bias with this form of 
evidence, does not allow it to be utilised for risk quantification or for providing proof of 
causality. Post marketing surveillance, a form of pharmaco-vigilence, is another important 
source of safety data. This information may be made available through institutional 
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reporting schemes, such as the FDA’s Adverse Events Recording System (AERS) in the 
United States (FDA, 2011) or the MHRA’s Yellow Card System in the United Kingdom 
(MHRA, 2011). Important information may come from drug specific data such as the TREAT 
registry (Lichtenstein et al., 2006), which is an on-going large-scale observational registry 
that was designed to examine the safety of Crohn’s Disease therapies including infliximab. 
This type of data provides a real world experience with a heterogeneous group of patients 
suffering a variety of co-morbidities and taking concomitant medication. However, such 
schemes are generally voluntary systems which are prone to under-reporting and hence an 
under estimation of true incidence. 
The low incidence of lymphoma, even in higher risk populations, poses a challenge to 
evaluating this risk. The incidence of all types of lymphoma diagnosed in the United 
Kingdom in 2007 was about 17 cases per 100,000 population (Cancer-Research-UK, 2011). A 
study of almost 3 million individuals would be necessary to detect an adverse event of this 
frequency with a confidence interval of 95%. No studies of this magnitude are available nor 
are likely to be available in the future. 
5.2 Available data 
The literature pertaining to the risk of lymphoma amongst IBD patients is dominated by 
case reports and case series. However, a number of large population studies have also been 
published over the last three decades which have been extremely valuable because they 
allow approximation of the risk of lymphoma (Loftus et al., 2000, Lewis et al., 2001, 
Beaugerie et al., 2009a, Greenstein et al., 1985). This information must be considered within 
the limitations of this type of study. A small number of meta-analyses have attempted to 
combine information from these population-based studies (Kandiel et al., 2005, Siegel et al., 
2009). Post-marketing surveillance for drugs such as azathioprine, mercaptopurine and 
methotrexate are not available but some data regarding the newer anti-TNF therapies in IBD 
now exists (Lichtenstein et al., 2006). 
Interest in the risk of developing lymphoma in the context of IBD and its treatment has 
grown exponentially (see Figure 3). This coincides with increasing use of 
immunomodulators in the management of IBD and concerns over their safety. Prior to the 
1990s, only sporadic case reports and case series were available. More recently, a number of 
population based studies, review articles and meta-analyses have been published which are 
discussed in this report. 
Additionally, changes in the classification of lymphoid neoplasia makes evaluation of the 
literature difficult in certain circumstances where there are overlapping features between 
diagnoses (Swerdlow et al., 2008). 
6. Presentation of lymphoma in IBD 
The presentation of lymphoma amongst IBD patients is very heterogenous and occurs in 
both Crohn’s disease and ulcerative colitis. 
There are abundant reports of lymphoma of the gastro-intestinal tract mimicking 
presentations of Crohn’s disease (Kashi et al., 2010, Kang et al., 2007, Hurlstone, 2002, Jouini 
et al., 2001, Vincenzi et al., 2001, Camera et al., 1997, Maaravi et al., 1993, Scully et al., 1993,  
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Fig. 3. Medline cited publications regarding lymphoma risk in IBD patients since 1950. 
McCullough et al., 1992, Pohl et al., 1991, Bartram and Chrispin, 1973) and ulcerative colitis 
(Isomoto et al., 2003, Luo et al., 1997, Wagonfeld et al., 1976, Myerson et al., 1974, Parnes et 
al., 1974, Friedman et al., 1968, Federman et al., 1963). Clearly, lymphoma of the GI tract 
frequently occurs in the absence of inflammatory bowel disease. In a series from the Mayo 
Clinic spanning 40 years in the pre-biologic era, of the 2,332 cases of primary intestinal 
lymphoma identified, only 15 patients had concomitant inflammatory bowel disease 
(Holubar et al., 2010). These cases are not discussed further here. 
6.1 Intestinal and extra-intestinal lymphoma  
Lymphoma may present at a variety of sites amongst IBD patient but these can broadly be 
classified as intestinal and extra-intestinal. 
Up to 15% of extra-nodal lymphoma involves the GI tract (Newton et al., 1997). In a series of 
15 cases of intestinal lymphoma, 60% were colorectal, 27% involved the small bowel and 
there were individual cases in the stomach, duodenum and ileal pouch, each constituting 
6.25% of this series (Holubar et al., 2010). In 80% of these cases, the location of the 
lymphoma was congruous to the site of IBD. In another series of 14 colorectal lymphomas, 
the commonest sites were the caecum and rectosigmoid but these were not IBD patients 
(Wong and Eu, 2006). Gastric mantle cell lymphoma has also been reported by Raderer et al 
in a patient with a 14 year history of Crohn’s disease (Raderer et al., 2004). Ileal pouch 
lymphoma has also been reported in a number of other publications (Sengul et al., 2008, 
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Frizzi et al., 2000, Nyam et al., 1997) and one publication suggests EBV may be involved in 
the aetiology (Schwartz et al., 2006). Lymphoma at an ileostomy site has also been reported 
(Pranesh, 2002). Metachronous colonic lymphoma (Hill et al., 1993) as well as synchronous 
colonic adenocarcinoma and lymphoma (Hope-Ross et al., 1985, Nishigami et al., 2010) have 
been described in IBD patients. 
In addition, a number of extra-intestinal sites of lymphoma amongst IBD patients have been 
reported. Hepatosplenic T-cell lymphoma (HSTCL) has become a concern amongst IBD 
physicians and this will be discussed in further detail. Owen et al reports a patient with UC 
treated with azathioprine who develops a B-cell lymphoproliferative disorder on her eyelid 
following a recent illness diagnosed as infectious mononucleosis (Owen et al., 2010). Deneau 
et al recently described the case of a child with an EBV-driven NK-cell lymphoma involving 
the skin and GI tract causing hepatosplenomegaly (Deneau et al., 2010). Other cutaneous 
lymphomas are described in the literature (Adams et al., 2004, Martinez Tirado et al., 2001). 
Vulval and peri-anal lymphoma has also been identified (Winnicki et al., 2009, 
Sivarajasingham et al., 2003). Kastner et al present a young lady with ulcerative colitis, 
previously treated with azathioprine, who presents with seizures and is found to have 
cerebral lesions of high grade B cell lymphoma (Kastner et al., 2007). Plamacytoma (a 
mature B-cell lymphoma) can present as a paravertebral mass (Redmond et al., 2007). 
6.2 Clinical presentation 
Many of the symptoms of intestinal lymphoma are very similar to those caused by 
inflammatory bowel disease. The most commonly presenting symptom is bloody diarrhoea 
occurring in almost three quarters of cases (Holubar et al., 2010, Wong and Eu, 2006). Other 
common symptoms include abdominal pain, weight loss and sweats. Presentation with 
bowel obstruction and perforation occurs less frequently (Holubar et al., 2010, Bourikas et 
al., 2008). Diagnosis of lymphoma is frequently made following laparotomy. Endoscopic 
appearances can be diverse, manifesting as ulceration, polyps or masses. 
Duration of IBD before development of lymphoma appears to be very variable between 
individual cases. Shepherd et al reported 10 cases of colorectal lymphoma complicating 
inflammatory bowel disease (6 patients with UC and 4 with CD) (Shepherd et al., 1989). The 
duration of inflammatory bowel disease varied from 30 months to 20 years in these cases. In 
the CESAME study, there was between 1 to 16 years of exposure to thiopurines before 
lymphoma diagnosis (Beaugerie et al., 2009a). 
More unusual presentations of lymphoma include jaundice due to a nodal mass at the porta 
hepatis in a patient with Crohn’s disease (Parasher et al., 1999), spontaneous tumour lysis 
syndrome in a Crohn’s patient with a plasmacytoma (Froilan Torres et al., 2009), nephrotic 
syndrome in a patient with Hodgkin’s lymphoma and UC (Basic-Jukic et al., 2002), and 
jaundice due to vanishing bile duct syndrome in a patient with Hodgkin’s lymphoma and 
IBD (DeBenedet et al., 2008). 
7. Population and cohort studies 
A number of population and cohort studies have been published and are described below. 
The standardised incidence ratio (SIR) is defined as the ratio between observed and 
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expected events in a study population. This is a useful comparator to analyse the risk of 
lymphoma in IBD patients and has been used in much of the literature. 
Incidence and Risk Factors for Lymphoma in a Single-Center Inflammatory Bowel 
Disease Population (Chiorean et al 2010) 
A cohort study identified 3,585 patients attending a single IBD centre in Indianapolis, USA. 
Data was collected retrospectively between 1990 and 2005. Since 2005, the registry was 
updated prospectively. An electronic database was interrogated for diagnoses of Hodgkin’s 
and non-Hodgkin’s lymphoma and compared to expected age-standardised incident rates 
from the SEER registry. This study also used a case matched control group with a ratio of 
1:10 to determine risk factors for lymphoma development. The population consisted of 2,277 
Crohn’s patients and 1,308 UC patients with no significant demographic differences 
between groups. 8 patients were identified with a diagnosis of lymphoma (6 NHL and 2 
HL). Only 3 patients had thiopurine exposure but 2 of these patients had also received TNF 
antagonists and were EBV positive. The study did not find any statistically significant 
relationship between diagnosis of lymphoma with demographics, drug therapy, duration of 
treatment and length of diagnosis. Based on SEER statistics, the overall SIR for lymphoma 
was 1.6 (95% CI 0.6 to 3.0) but this was not significant. (Chiorean et al., 2010) 
Risk of Cancer in Inflammatory Bowel Disease Treated with Azathioprine: A UK 
Population-Based Case-Control Study (Armstrong et al 2010) 
This was a nested case-control study using the General Practice Research Database (GPRD) 
in the UK which was interrogated for patients with a diagnosis of IBD, any previous 
prescriptions for azathioprine or mercaptopurine and a subsequent diagnosis of any cancer. 
The GPRD is the largest longitudinal primary care database in the world containing 
approximately 50 million patient years of data. The control group consisted of all IBD 
patients who had not been diagnosed with a cancer. The total number of patients included 
in the study was 15,471 and 15 patients had diagnoses of lymphoma (2 HL, 6 NHL and 7 
unspecified). The group found the risk of lymphoma for patients who had ever received 
thiopurines versus those that had never received such drugs was increased by an OR of 3.22 
(95% CI 1.01 to 10.18). An SIR was not calculated for the risk of lymphoma compared to the 
background population in this study. (Armstrong et al., 2010) 
Lymphoproliferative Disorders in an Inflammatory Bowel Disease Unit (Van Domselaar 
et al 2010) 
This was a retrospective study of 911 patients attending a tertiary IBD clinic in Madrid 
followed up for a mean of 32.3 months. There were 7 cases of lymphoma identified in the 
cohort (6 NHL and 1 HL). The mean age at diagnosis was 53 years and the mean time from 
IBD to lymphoma diagnosis was 4.82 years (range 0 to 20 years). Three cases were 
associated with EBV. An SIR of 3.72 can be calculated from the figures presented though this 
was not calculated by the authors. (Van Domselaar et al., 2010) 
Risk of Malignant Lymphoma in Patients with Inflammatory Bowel Diseases: A Dutch 
Nationwide Study (Vos et al) 
The authors identified all IBD patients diagnosed with lymphoma between 1997 and 2004 
from a Dutch nationwide histo- and cyto-pathology database known as PALGA. Age 
adjusted incidence of lymphoma was obtained from the Netherlands Central Bureau for 
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Statistics between these years. After excluding incomplete data, 44 cases of lymphoma were 
identified in 17,834 IBD patients. The calculated SIR was 1.27 (95% CI 0.92 to 1.68) and the 
authors concluded that there was no increased risk of lymphoma in IBD patients. However, 
the SIRs in the age groups 35-39 years and 45-49 years were 9.32 and 3.99 respectively and 
these did reach significance. Only 43% of patients were exposed to thiopurines. Of the 
patients in whom EBV status could be obtained, 92% (11/12) with EBV positive lymphoma 
were taking a thiopurine compared to 19% (4/21) who were EBV negative (p<0.001). (Vos et 
al., 2010) 
Lymphoproliferative Disorders in Patients Receiving Thiopurines for Inflammatory 
Bowel Disease: A Prospective Observational Cohort Study (Beaugerie et al 2009) 
This is a frequently quoted study which set out to objectively clarify the risk of cancer in IBD 
patients. 19,486 patients were enrolled into a prospective French nationwide database called 
CESAME (Cancers et Surrisque Associé aux Maladies inflammatoires intestinales En France) 
between May 2004 and June 2005 and followed up until 31st December 2007. This equated to 
almost 50,000 patient-years of follow up. Details regarding patient demographics, type of 
IBD, date of diagnosis, disease location, history of malignancy and exposure to 
immunosuppressive therapy including thiopurines, methotrexate and anti-TNF agents were 
collected. A total of 23 patients were identified who developed lymphoma (22 NHL, 1 HL). 
The SIR is not presented in this study but later discussed in a review article by the same 
author at 1.86 (95% CI 1.1 to 3.0) (Sokol and Beaugerie, 2009). The HR for patients taking 
AZA versus those who were not was 5.28 (95% CI 2.01 to 13.9). There was a trend towards 
increased risk of lymphoma with anti-TNF therapy but this did not reach statistical 
significance. No patients taking methotrexate developed lymphoma in this study. 
(Beaugerie et al., 2009a) 
Risk of Haematopoietic Cancer in Patients with Inflammatory Bowel Disease (Askling et 
al 2005) 
This was a huge population based cohort study using prospectively recorded data from a 
number of large Swedish IBD databases (Uppsala cohort, Stockholm County cohort, 
Stockholm pan-colitis register and Swedish in-patient register). 47, 679 patients were 
recruited in total and 180 lymphomas were detected. Compared to national Swedish cancer 
statistics, the calculated SIR was 1.09 in this study. (Askling et al., 2005) 
Intestinal and Extra-Intestinal Cancer in Crohn’s Disease: Follow-up of a Population-
based Cohort in Copenhagen, Denmark (Jess et al 2004) 
374 patients with a diagnosis of Crohn’s disease were followed up for a median of 17 years 
in Copenhagen County. No lymphomas were observed in this population. (Jess et al., 2004) 
Long-term Risk of Cancer in Ulcerative Colitis : A Population-based Cohort Study from 
Copenhagen County (Winther et al 2004) 
This study is from the same cohort of patients investigated in the above study by Jess et al. 
In the sample of 1160 UC patients, the median follow up was 19 years. A total of 124 
malignancies were observed including only 1 lymphoma. The SIR for lymphoma risk works 
out at 0.5 ( 95% CI 0.1 to 0.8) in this study. This suggests a protective role of UC in 
lymphomagenesis which is not demonstrated in any other studies. This result is likely to be 
artefactual due to the finding of only 1 case of lymphoma in the study. (Winther et al., 2004) 
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Inflammatory Bowel Disease is not Associated with an Increased Risk of Lymphoma 
(Lewis et al 2001) 
This is an important large retrospective cohort study utilising the General Practice Research 
Database that was also used by Armstrong et al above. All patients coded with a diagnosis of 
UC or CD were eligible for inclusion and cross-matched for a diagnosis of HL and NHL. 
Prescriptions for AZA and 6MP were also analysed and an average dose per day was 
calculated. A control cohort was randomly selected but matched for age, sex and primary care 
practice. The study identified 6,605 patients with CD, 10,391 patients with UC and there were 
60,506 patients in the control group. 18 patients were identified with lymphoma in this cohort 
compared with an expected 13.6 cases and an SIR of 1.32 (95% CI 0.78 to 2.10). The relative risk 
compared to the control group was 1.20 (96% CI 0.67 to 2.06). The authors concluded that IBD 
was not associated with an increased risk of lymphoma. Even on sub-analysis of patients 
prescribed thiopurines, there was no significant increased risk of lymphoma. (Lewis et al., 2001) 
Cancer Risk in Patients with Inflammatory Bowel Disease – A Population-based Study 
(Bernstein et al 2001) 
Population-based data was obtained from the University of Manitoba IBD database which 
was extracted from the Manitoba Health administrative databases in Winnipeg, Canada. An 
age and gender matched non-IBD control group was randomly selected with a ratio of 1:10. 
5,529 patients were included in the study and the overall incidence of cancer was 690.2 per 
100,000 population. 16 cases of NHL were identified but no cases of HL. This study found an 
incident rate ratio of 1.59 (95% CI 0.6 to 3.3) for the risk of lymphoma. The risk of developing 
lymphoma was highest in male patients with Crohn’s disease where the IRR was calculated 
at 3.63 (95% CI 1.53 to 8.62). (Bernstein et al., 2001) 
The Incidence of Lymphoid and Myeloid Malignancies Among Hospitalized Crohn’s 
Disease Patients (Arseneau et al 2001) 
This was a retrospective cohort study. Discharge data for all in-patients in the 
Commonwealth of Virginia and the State of California was analysed to identify patients 
who were admitted to hospital with a diagnosis code for Crohn’s disease. These patients 
were then followed up for 2 years examining for new diagnostic codes for lymphoma. The 
patients were matched with a control group who had admissions to hospital over the same 
period with no history of CD. 5,426 patients were discharged from hospital in the study 
period with a diagnosis of CD. 10 cases of NHL were identified and an OR of 2.04 (95% CI 
1.33 to 3.14) was calculated. (Arseneau et al., 2001) 
Hodgkin’s Disease Risk is Increased in Patients with Ulcerative Colitis (Palli et al 2000) 
This is a population based study of all patients with IBD residing in Florence, Italy between 
1978 and 1992. A total of 920 patients were followed up for a median of 11 years. An 
increased risk of Hodgkin’s disease was observed in patients with UC with 6 cases 
identified and an SIR calculated at 9.3 (95% CI 2.5 to 23.8). The broad confidence interval 
makes it difficult to assess the validity of these findings in this study. (Palli et al., 2000) 
Risk of Lymphoma in Inflammatory Bowel Disease (Loftus et al 2000) 
This was a retrospective study of all incidence cases of IBD in Olmsted County, Minnesota 
between 1950 and 1993 examined for the diagnosis of lymphoma. The authors comment that 
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the use of immunomodulators during this time frame was rare and hoped to be able to 
demonstrate the baseline risk of lymphoma in IBD patients. Expected cases of lymphoma 
were derived from published Olmsted County age-standardised incidence rates. 454 
patients were diagnosed with IBD in the study period. Only 1 case of NHL was identified in 
the entire cohort and an SIR of 1.0 (95% CI 0.03 to 5.6) was calculated. The observed number 
of patients with lymphoma is so small in this study that the results are very difficult to 
interpret. (Loftus et al., 2000) 
Increased Incidence of non-Hodgkin’s Lymphoma in Inflammatory Bowel Disease 
Patients on Immunosuppressive Therapy but Overall Risk is Low (Farrell et al 2000) 
This study interrogated an IBD database of 782 IBD patients in Dublin. 30% of patients were 
taking immunomodulators therapy with the majority on azathioprine. A total of 30 cancers 
were identified with 4 cases of NHL compared with the expected 0.53 cases. These figures 
produced an SIR of 31.2 (95% CI 2.0 to 85.0). All these patients were on immunosuppressive 
therapy (2 on MTX and 2 on AZA). Calculating an SIR for patients on immunosuppressive 
therapy, the authors found a 58.8 –fold increased risk. These rather alarming results have 
not been duplicated. The confidence intervals are very broad and difficult to interpret. A 
possible explanation for these outlying results is that this retrospective study was initiated 
shortly after two new cases of lymphoma had been identified in this cohort. This clustering 
of cases may have had a significant impact on risk calculations. (Farrell et al., 2000) 
Increased Risk of Cancer in Ulcerative Colitis: A Population-based Cohort Study (Karlén 
et al 1999) 
A cohort of 1547 patients with UC in Stockholm County diagnosed between 1955 and 1984 
were followed on the National Cancer Register and the National Cause of Death Register 
until 1989. Comparisons were made with regional cancer statistics. 3 lymphomas were 
identified in the cohort with an SIR of 1.2 (95% CI 0.3 to 2.5). (Karlen et al., 1999) 
Long-term Neoplasia Risk after Azathioprine Treatment in Inflammatory Bowel Disease 
(Connell et al 1994) 
This study from St Mark’s Hospital in London followed up 755 IBD patients taking 
azathioprine for a median of 12.5 months. The overall risk of cancer was similar to that of 
the background population with an SIR of 1.27 but there was an increased risk of colorectal 
malignancy with an SIR of 6.7. No cases of lymphoma were identified in this cohort. 
(Connell et al., 1994) 
Crohn’s Disease and Cancer: A Population-based Cohort Study (Persson et al 1994) 
This study was performed by the same group and used similar methodology to the Karlén 
study from Stockholm described above. 1251 patients with Crohn’s disease were followed 
up. There was an increased incidence of small bowel and upper GI tract malignancies. 4 
cases of lymphoma were identified with an SIR of 1.4 (95% CI 0.4 to 3.5). (Persson et al., 
1994) 
Extracolonic Malignancies in Inflammatory Bowel Disease (Ekbom et al 1991) 
This was a population based cohort with IBD consisting of 4776 patients from the Uppsala 
Health Care Region in central Sweden. All patients were followed up in the Swedish Cancer 
Registry and the Registry of Causes of Death for a diagnosis of malignancy. 9 cases of 
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lymphoma were found in this cohort with an expected 8.9 cases. The SIR was 1.0 (95% CI 0.5 
to 1.6). (Ekbom et al., 1991) 
Extraintestinal Cancers in Inflammatory Bowel Disease (Greenstein et al 1985) 
This was a retrospective case note review of patients with a diagnosis of IBD at the Mount 
Sinai Hospital, New York. 1961 patients were studied with a total of 8 lymphomas (6 NHL 
and 2 HL). The expected frequency of lymphoma expected was 1.67 giving an SIR of 4.79. 
(Greenstein et al., 1985) 
8. Baseline risk of lymphoma in IBD 
An estimate of the baseline lymphoma risk has been made for this chapter using a meta-
analysis technique. Populations and cohort studies were identified using the MEDLINE 
database provided by the US National Library of Medicine (NLM). Statistical analysis was 
carried out using the Review Manager (RevMan) Version 5 software which is provided by 
The Cochrane Collaboration, Copenhagen, for preparing and maintaining Cochrane reviews 
and meta-analyses. Dichotomous data was entered and analysed using the Mantel-
Haentszel statistical technique and a 95% confidence interval assuming a Poisson 
distribution of lymphoma incidence. Studies were only weighted by their size. Graphical 
representation of results is performed with a Forest plot indicating 95% confidence intervals.  
A total of 145,208 patients from 16 trials were included in the meta-analysis (see Figure 4). This 
produced a cumulative Risk Ratio of 1.29 (95% CI of 1.10 to 1.51, p=0.002). However, this 
included hospital-based and specialist clinic cohorts which can introduce selection bias. The 
meta-analysis was repeated only including the 12 population-based studies (see Figure 5). 
133,463 patients were included. This did not have a very large effect on the results and the Risk 
Ratio falls slightly to 1.23 (95% CI 1.05 to 1.45, p=0.01). In both analyses, the test for 
heterogeneity was not significant and the test for overall effect was 3.15 and 2.52 respectively. 
 
Fig. 4. Meta-analysis of population and cohort studies to evaluate the baseline risk of 
lymphoma.  
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Fig. 5. Meta-analysis of population studies only to evaluate risk of lymphoma.  
These findings would suggest that there is only a small (if any) increased risk of lymphoma 
in IBD patients compared to the general population. 
9. Risk of lymphoma with thiopurines 
The risk of lymphoma in patients treated with thiopurines has been analysed by including 
all cohort and population-based studies (see Figure 6). There were 35805 patients included 
from 7 studies. The test for heterogeneity was not significant and the test for overall effect 
was 4.03. Overall Risk Ratio is calculated at 3.54 (95% CI 1.91 to 6.54, p<0.0001) confirming 
the suspected increased risk of lymphoma in patients treated with azathioprine or 
mercaptopurine. 
 
Fig. 6. Meta-analysis to evaluate the risk of lymphoma in patients treated with thiopurines. 
10. Comparison to other published meta-analyses 
Only three meta-analyses have investigated the background risk and the thiopurine-
associated risk of lymphoma in IBD patients. Results from Von Roon et al and Kandiel et al 
support the findings of the meta-analyses produced here but the work by Masunaga et al 
shows some disparity. 
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The Risk of Cancer in Patients with Crohn’s Disease (Von Roon et al 2007) 
Meta-analytical techniques were used to quantify the risk of intestinal, extra-intestinal and 
haemopoietic malignancies in Crohn’s patients. 34 studies were included with a total of 
61,122 patients. Overall pooled estimates were obtained using a random-effects model. The 
relative risk of lymphoma was 1.42 (95% CI 1.16 to 1.73). This publication, similar to the 
meta-analysis presented in this dissertation, suggests only a slight increased baseline risk of 
lymphoma compared to the general population. (von Roon et al., 2007) 
Increased Risk of Lymphoma among Inflammatory Bowel Disease Patients Treated with 
Azathioprine and 6-Mercaptopurine (Kandiel et al 2005) 
This meta-analysis sought to provide an estimate of the relative risk of lymphoma among IBD 
patients treated with thiopurine therapy. Inclusion criteria were strict with only cohort studies 
in the English language, where the exposed group had received AZA or 6MP and the study 
had been specifically designed to evaluate the risk of cancer. 6 studies were included with a 
total of 3891 IBD patients. Similar methodology was used to the presented meta-analysis in 
this dissertation. Results were also pooled using a Mantzel-Haenszel method but weighting 
was proportioned to the inverse variance rather than the population size. 
The pooled data identified 11 cases of lymphoma whilst the expected number of cases was 
2.63, resulting in an SIR of 4.18 (95% CI 2.07 to 7.51). This is similar in magnitude to the SIR 
in the meta-analysis presented here at 3.54. However, Kandiel et al found a significant test of 
heterogeneity explained by the substantially higher rates of lymphoma in two of the 
included studies (Farrell et al 2000 and Connell et al 1994). Exclusion of these studies did not 
produce a large impact on the pooled SIR. (Kandiel et al., 2005) 
Meta-Analysis of Risk of Malignancy with Immunosuppressive Drugs in Inflammatory 
Bowel Disease (Masunaga et al 2007) 
This group aimed to compare the risks of developing malignancy in IBD patients receiving 
immunosuppressants with those who were not. 9 cohort studies met the inclusion criteria. 
Where a control group for comparison was not available in these studies, Masunaga et al 
compared incidence of lymphoma with that of the University of Manitoba IBD Database 
used by Bernstein et al in their population study. The meta-analysis technique calculated a 
Weighted Mean Difference (WMD) rather than SIR at 0.0 (95% CI -0.8 to 0.7). These results 
were not significant and the authors concluded that there was no increased risk of 
lymphoma in IBD patients treated with immunosuppressives. This result seems to deviate 
from the findings of the larger recent population studies (such as the CESAME study), that 
of the meta-analysis performed by Kandiel et al and the meta-analysis presented in this 
dissertation. This may be due to bias introduced by the arbitrary control method used to 
calculate expected lymphoma rates in control groups in this meta-analysis. (Masunaga et al., 
2007) 
11. Risk of lymphoma in patients treated with methotrexate 
There is virtually no data for the risk of lymphoma in IBD patients taking methotrexate. 
Only 2 cases of lymphoma associated with MTX treatment for inflammatory bowel disease 
have been reported in the literature (Farrell et al., 2000). In this study, 31 patients were 
receiving methotrexate and two of them were subsequently diagnosed with lymphoma. One 
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of these patients had also received cyclosporin A. As discussed earlier, the authors of this 
study found risk of lymphoma in their IBD cohort to be much higher than is reported 
elsewhere and this deviation may have resulted from a clustering of lymphoma diagnosis at 
the time of investigation. No reliable determination of risk can be obtained from this study. 
In the large CESAME study, almost 700 patients (4%) had on-going or previous MTX use 
but no cases of lymphoma were identified in these patients (Beaugerie et al., 2009a). 
Some information can be extrapolated from studies of other inflammatory conditions 
though this data must be applied with caution in IBD because the risk of the drug cannot be 
easily separated from the risk of the disease itself. Lymphoma associated with methotrexate 
has been reported in the rheumatology literature. 
A large observational study of rheumatoid arthritis patients treated with methotrexate 
and/or anti-TNF drugs followed up 18,572 patients biannually found an SIR of 1.7 (95% CI 
0.9 to 3.2). The authors concluded that there was no significant increased risk of lymphoma 
with methotrexate therapy over baseline (Wolfe and Michaud, 2004). A French 3 year 
prospective population study of RA patients treated with methotrexate identified 18 cases of 
NHL and 7 cases of HL. Compared to national population statistics, the authors found no 
increased risk of NHL but a Standardised Mortality Ratio of 7.4 (95% CI 3.0 to 15.3) for HL 
in their cohort (Mariette et al., 2002). 
There are no similar studies in IBD and it is not possible to evaluate a relative or absolute 
risk of lymphoma with methotrexate therapy. However, it would appear that the risk of 
lymphoma in this patient group is low. 
12. Risk of lymphoma in patients treated with anti-TNF drugs 
It is difficult to assess the specific risk of anti-TNF drugs in IBD patients because most 
patients will have had thiopurine or methotrexate exposure prior to using this modality of 
treatment. The bulk of the literature regarding anti-TNF drugs is for the use of infliximab in 
Crohn’s disease and little is known regarding differences in safety when used in UC. 
A meta-analysis has recently been carried out by Siegel et al with very comprehensive 
methodology (Siegel et al., 2009). In this meta-analysis, 26 studies with a total of 8905 
patients with 21,178 patient-years of exposure to anti-TNF drugs were included (see Table 
2). 22 studies were regarding infliximab, 3 regarding adalimumab and only one regarding 
certolizumab. All the included studies were for the treatment of Crohn’s disease through 
randomised controlled trials, cohort studies and case series. There were 13 cases of NHL 
with a mean age at presentation of 52 years and 62% male. 10 out of the 13 patients with 
NHL had received dual therapy with immunomodulators and anti-TNFs. The SIR for the 
risk of lymphoma in patients treated with anti-TNF drugs was 3.23 (95% CI 1.5 to 6.9) 
compared to SEER statistics (see Table 3). However, the majority of the lymphoma patients 
had previously had exposure to immunomodulators and the SIR calculated for anti-TNF 
therapy should actually be referred to as the risk of combination therapy. This numerical 
result is in the same order of magnitude as the risk for immunomodulator therapy alone (as 
calculated by the meta-analysis in this dissertation and other studies). This may suggest that 
immunomodulator therapy may play the dominant role in lymphoma risk even in settings 
where combination therapy is used. 
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Study Year Setting Drug N 
Median 
f/u 
(weeks) 
NHL 
cases 
Colombel et al 2007 PRECISE RCT CTZ 905 53 0 
Colombel et al 2007 OLE of GAIN and CHARM ADA 1169 58 0 
Sandborn et al 2007 CLASSIC II RCT ADA 276 56 1 
Lemann et al 2006 RCT IXB + AZA IXB 57 52 0 
Schroder et al 2006 
Controlled pilot study of 
IXB + MTX
IXB 19 48 0 
Mantzaris et al 2004 RCT IXB + AZA IXB 45 60 0 
Sands et al 2004 IXB for fistulising CD IXB 282 54 0 
Hanauer et al 2002 ACCENT I IXB 573 54 1 
Rutgeerts et al 1999 RCT IXB 73 48 6 
Lichtenstein et 
al 
2007 TREAT registry IXB 3396 201 0 
Biancome et al 2006 Matched pair study IXB 404 109 1 
Doumit et al 2004 Cohort study IXB 322 104 0 
Carbone et al 2007 Case series IXB 34 52 0 
Peyrin-
Biroulet et al 
2007 
Case series for switch to 
ADA
ADA 52 52 0 
Hyder et al 2006 Case series for fistulising CD IXB 22 91 0 
Pacault et al 2006 Case series IXB 137 150 0 
Talbot et al 2005 Case series for perianal CD IXB 21 87 0 
Choi et al 2005 Case series from Korea IXB 13 57 0 
Ardizzone et 
al 
2004 Case series for perianal CD IXB 20 67 0 
Colombel et al 2004 
Case series from Mayo 
Clinic
IXB 500 74 1 
Rodrigo et al 2004 Case series for fistulising CD IXB 44 72 0 
Schroder et al 2004 
Case series IXBMTX in 
fistulising CD
IXB 12 57.6 0 
Sciderer et al 2004 Cohort study IXB 92 113 0 
Ljung et al 2003 Population-based cohort IXB 191 52 3 
Kinney et al 2003 Case series IXB 117 52 0 
Cohen et al 2000 Case series IXB 129 52 0 
Table 2. Studies included in meta-analysis By Siegel et al 2009. (ADA adalimumab; CTZ 
certolizumab, MTX methotrexate, AZA azathioprine, CD Crohn’s disease, RCT randomised 
controlled trial, f/u follow up, OLE open label extension). 
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 NHL rate per 10,000 patient-years SIR 95% CI 
SEER (all ages) 1.9   
IM alone 3.6   
Anti-TNF vs SEER 6.1 3.23 1.5 to 6.9 
Anti-TNF vs IM alone 6.1 1.7 0.5 to 7.1 
Table 3. Results of meta-analysis by Siegel et al 2009. 
The majority of these studies have relatively small numbers of patients, short follow up and 
were not designed to evaluate efficacy. However, the TREAT registry data includes the 
largest number of patients and has the longest follow up. The TREAT (Crohn’s Therapy, 
Resource, Evaluation and Assessment Tool) registry is a large prospective, observational, 
multi-centre, long-term registry of Crohn’s disease patients designed to evaluate the safety 
of infliximab and is a form of post-marketing surveillance. The TREAT registry is hoped to 
represent real world patients without the biases inherent to patients included in trials. No 
cases of lymphoma were reported in the registry. 
The CESAME study data was not included in the meta-analysis by Siegel et al. Beaugerie et 
al calculated SIRs depending on anti-TNF and thiopurine combination or mono-therapy as 
well as whether drugs were continued or discontinued (Beaugerie et al., 2009a). These 
results are presented in Table 4. The results cannot confirm an increased risk of lymphoma 
in those continuing anti-TNF therapy because the confidence interval crosses 1.0. However, 
there does appear to be an increased risk when anti-TNF drugs have been used with 
thiopurines, particularly when combination therapy is continued.  
 
 
NHL 
cases 
SIR 95% CI 
Continuing anti-TNF therapy 2 4.53 0.55 to 16.4 
Discontinued anti-TNF therapy 3 6.92 1.43 to 20.2 
Continuing thiopurines and anti-TNF therapy 2 10.2 1.24 to 36.9 
Continuing thiopurines but discontinued or never anti-TNFs 13 6.53 3.48 to 11.2 
Table 4. SIRs in patients treated with thiopurines and anti-TNF drugs (Beaugerie et al 2009) 
13. Hepatosplenic T-cell lymphoma 
Hepatosplenic T-cell lymphoma (HSTCL) is a rare form of peripheral non-Hodgkin’s 
lymphoma. In the majority of incidences, it results from a clonal expansion of Ǆ/ǅ T-cells 
but ǂ/ǃ T-cell receptors can also be expressed in some cases (Gaulard et al., 1990). Only 100 
to 200 cases of HSTCL in the entire medical literature have been reported (Belhadj et al., 
2003) but there has been recent concern regarding the safety of thiopurines and anti-TNF 
therapy, particularly when used in combination, for the management of IBD. To date, 36 
cases of HSTCL have been reported in IBD patients (Kotlyar et al., 2011), mostly affecting 
young men and the prognosis has been invariably fatal. Despite treatment with 
chemotherapy and stem cell transplantation, median survival is only 11 months (Falchook et 
al., 2009) but novel treatment strategies have shown some promise in isolated cases (Jaeger 
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et al., 2008, Tey et al., 2008). Diagnosis is made by liver, splenic or bone marrow biopsy 
exhibiting atypical medium-sized lymphoid cells with round nuclei, small distinct nucleoli, 
loosely condensed chromatin, moderate pale cytoplasm and particular immunophenotypic 
expression which will be discussed further (Swerdlow et al., 2008). 
13.1 Clinical presentation 
The aberrant cells infiltrate into the sinusoids of the spleen, liver and bone marrow resulting 
in the classical presentation of hepatosplenomegaly with thrombocytopenia but no 
lymphadenopathy. Systemic B symptoms of fever, night sweats and weight loss may affect 
up to 80% of patients. Other findings may include anaemia, abnormal liver function tests 
and less frequently atypical lymphocytes on peripheral blood film (Falchook et al., 2009). 
13.2 Immunophenotypic and genetic features 
The tumour cells express CD2, surface CD3, CD7 and CD16 but there is absence of CD4, 
CD5, CD8 and the B-cell surface marker CD20 (Swerdlow et al., 2008). Most cases express 
the Ǆ/ǅ T-cell receptor (TCR-Ǆ positive) but rarer cases express the ǂ/ǃ T-cell receptor (TCR-
ǃ positive) and studies demonstrate clonal rearrangements of the TCR gene. 
A recent systematic review investigating chromosomal abnormalities in IBD patients 
diagnosed with HSTCL identified the development of isochrome 7q in 57.1%, aberrations of 
chromosome 8 in 35.7%, trisomy 8 in 21.4% and loss of the Y chromosome in 14.3 % of cases 
(Kotlyar et al., 2010). The group were intrigued by the cases with loss of the Y chromosome 
as almost all cases of HSTCL have presented in men. These chromosomal abnormalities are 
not specific to IBD patients. 
13.3 HSTCL in IBD 
HSTCL is not linked to EBV infection. However, the risk of HSTCL does seem to be related 
to thiopurine and anti-TNF therapy. DNA damage specific to chromosome 7 has been seen 
in a dose dependent manner with thiopurine agents (Piccin et al., 2010) and inhibition of 
TNF may result in decreased effectiveness of immune surveillance eliminating cells with 
aberrant abnormal chromosomal pattern (Shale et al., 2008). 
Early concern was regarding a risk of HSTCL in IBD patients who had previous exposure to 
both thiopurines and anti-TNF drugs but more and more cases have been identified with 
only thiopurine exposure. Anti-TNF drugs are frequently used in non-IBD conditions, such 
as rheumatoid arthritis, ankylosing spondylitis and psoriasis, but they are rarely used in 
combination with other immunomodulators. It is interesting that, HSTCL has only been 
reported in a single non-IBD patient who received adalimumab for rheumatoid arthritis 
(Shale et al., 2008). Conversely, there are a number of case reports of patients developing 
HSTCL whilst on immunosuppression in the post-transplant setting (Roelandt et al., 2009, 
Tey et al., 2008, Steurer et al., 2002) where anti-TNF drugs are not used. 
Kotlyar et al recently presented a systematic review investigating medications, duration of 
therapy and ages of IBD patients diagnosed with HSTCL (Kotlyar et al., 2011). 36 cases of 
HSTCL have occurred in IBD patients since 1996, all of whom had a history of thiopurine 
exposure. 20 of these patients also had also received anti-TNF therapy. Four patients had 
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previously received both infliximab and adalimumab and an additional patient had received a 
third biologic, natalizumab. There were no patients who had received an anti-TNF drug alone. 
Most patients had received at least 2 years therapy with a thiopurine and of those patients who 
had received infliximab, the number of previous infusions ranged from 1 to 20 up to 5 years 
prior to the diagnosis of HSTCL. The age range of patients was 12 to 58 years with a median of 
23 years. The majority of patients were under 35 years old and the older patient appears to be 
an isolated case. Of the 31 patients in whom gender was known, only two were female. 
13.4 Clinical application 
From the limited information available, HSTCL seems to be linked to previous prolonged 
thiopurine exposure and the risk may be higher in those who have also received an anti-
TNF drug. This seems to compete with conclusions drawn from recent efficacy trials. The 
SONIC trial found that combination therapy with azathioprine and infliximab reached 
significantly higher rates of steroid-free clinical remission than either of these drugs as 
monotherapy for a cohort of naïve patients with moderate to severe Crohn’s disease (24.1% 
vs 34.9% vs 46.2% AZA vs IXB vs AZA+IXB at 50 weeks) (Colombel et al., 2010). 
Whilst it is not possible to estimate the relative risk of HSTCL in IBD patients, Kotlyar et al 
attempted to derive the absolute risk of HSTCL in men using epidemiology data from the 
US and Europe as well as an estimate of thiopurine use in IBD patients from the French 
CESAME trial (Beaugerie et al., 2009a, Kotlyar et al., 2010). The group concluded that more 
than 99.99% of patients in immunomodulatory treatment will not develop HSTCL. Further 
reassurance comes from the CESAME study in that no cases of HSTCL were found despite 
analysis of over 50,000 patient-years follow up. 
A vigilant approach must be taken when using thiopurines for the treatment of male 
patients under 35 years. Kotlyar et al recommended careful monitoring in patients who have 
been on thiopurine treatment for more than 2 years but this may be difficult to put in to 
practice as no pre-malignant markers have been identified. Decisions between the use of 
combination or monotherapy must be made in the context of clinical severity of disease and 
poor prognostic markers for complicated IBD. The risk of HSTCL is extremely low and 
patients should be made aware of this when making choices regarding their treatment. 
Highly efficacious therapeutic strategies should not be rejected based entirely on the low 
risk of HSTCL. Somewhat reassuringly, despite the rapidly increasing number of patients on 
anti-TNF drugs, exceeding 5 million patient-years exposure, the rate at which new cases of 
HSTCL have been diagnosed has not changed over the last 15 years. 
14. Confounding factors and limitations 
There are a number of limitations to the data which has been pooled for the meta-analyses 
presented in this chapter. There are also confounding factors which are not taken in to 
account by the source studies. 
14.1 Age 
Data from the US and UK clearly demonstrates that the incidence of non-Hodgkin’s 
lymphoma, the predominant form of lymphoid neoplasm seen in IBD patients, increases 
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with advancing age (see Figure 2). Most of the studies reviewed in this chapter use age 
standardised statistics to estimate risk of lymphoma in IBD patients. An earlier meta-
analysis carried out by Kandiel et al, found a relative risk for the development of lymphoma 
in IBD patients treated with thiopurines of 4.18 (95% CI 2.07 to 7.51) which is comparable to 
the findings of the meta-analysis presented here. The authors went on to calculate the 
number of patients that would need to be treated for each new diagnosis of lymphoma i.e. 
the number needed to harm (NNH). Approximating to a relative risk of 4, the NNH varied 
from 4357 in 20-29 year olds to just 355 in 70-79 year olds (Kandiel et al., 2005). The risk of 
lymphoma is not uniform across all age groups and this needs to be taken in to account 
when this information is applied to a clinical setting. 
14.2 Gender 
Gender also appears to be a further factor when analysing the risk of both Hodgkin’s and 
non-Hodgkin’s lymphoma. Although other autoimmune conditions tend to affect more 
women, the gender difference for IBD is small. Men have an increased risk of lymphoma 
(see Figure 2 and Figure 3) but the magnitude of the gender difference varies with age and 
type of lymphoma. In NHL there is only a slight preponderance for males but in HL, the 
incidence is three times greater in males in certain age groups. As discussed, HSTCL occurs 
almost exclusively in young men. Many of the studies in this analysis did not separate 
results for male and female patients but this may have made analysis difficult because of the 
generally small number of cases of lymphoma detected in these cohorts. Vos et al, in their 
nationwide Dutch study, calculated SIRs for male and female patients separately but did not 
find a substantial difference when they took both groups as a whole. However, in the 35-39 
years age range, males had an SIR of 10.25 (95% CI 2.56 to 23.05) and females, 6.74 (95% CI 
1.20 to 16.77) and this difference was significant (Vos et al., 2010). 
14.3 Type of lymphoma 
Non-Hodgkin’s lymphoma appears to be the predominant lymphoid malignancy detected 
in IBD patients, particularly diffuse large B-cell lymphoma (DLBCL). The CESAME study 
group found 22 cases of NHL and only 1 HL in their large cohort of patients from France 
(Beaugerie et al., 2009a). Few studies have attempted to separate findings for HL and 
NHL. Palli et al did find an increased risk of HL in patients with UC but the confidence 
interval was large and the validity of these results has been put in to question (Palli et al., 
2000). 
14.4 Type of IBD 
Whether Crohn’s disease or ulcerative colitis confers a higher risk of lymphoma has not 
been established. Two publications from the same population-based cohort in Copenhagen, 
Denmark distinguished their analysis between CD and UC patients. In the CD group no 
lymphomas were identified and only 1 lymphoma was found in the UC group (SIR 0.5) 
(Winther et al., 2004, Jess et al., 2004). A further population-based cohort from Stockholm, 
Sweden also analysed UC and CD separately in two different publications. Again no cases 
of lymphoma were seen in the CD group but there were 3 in the UC group (SIR 1.2) (Persson 
et al., 1994, Karlen et al., 1999). Interpreting these findings with such small numbers is 
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fraught with difficulty. In the CESAME study, 16 of the 23 lymphomas were in patients with 
Crohn’s disease (Beaugerie et al., 2009a).  
14.5 Exposure to immunomodulators 
Not all studies have attempted to evaluate the risk of lymphoma associated with 
immunomodulator therapy. The studies which have attempted to make this estimation are 
heterogenous and frequently there is a lack of distinction between lifetime exposure to these 
drugs, the cumulative doses received and whether cessation of a drug returns any 
lymphoma risk back to baseline. The CESAME study group attempted to answer some of 
these questions (Beaugerie et al., 2009a) by analysing patients who have continuing, 
discontinued or never received thiopurines. The SIRs for these three groups were 6.86 (95% CI 
3.94 to 11.31), 1.44 (95% CI 0.17 to 5.20) and 1.43 (CI 95% 0.53 to 3.12) respectively. This may 
suggest that discontinuation of thiopurines returns risk to baseline but the results were not 
statistically significant. 
14.6 Disease severity 
It is not clear whether it is the disease itself, its treatment or a combination of the two which 
might put IBD patients at increased risk of lymphoma. It is possible that the use of drugs such 
as thiopurines and biologics are a marker of more aggressive disease and it is disease severity 
which disposes to lymphoma development. However, modern management of IBD has led to 
earlier use of these drugs, often in patients who do not have severe disease but possess risk 
factors for complicated disease, in an attempt to alter the natural history of the condition. 
Severity of disease as a risk factor for lymphoma has not been analysed in any depth in IBD 
patients but there is some evidence available from other autoimmune diseases. A study of 
378 RA patients diagnosed with lymphoma found no significant association with individual 
drugs but a marked increased risk with high disease activity which conferred a 70-fold 
increased risk (Baecklund et al., 2006). The authors concluded that it was the disease 
activity, not its treatment that was important in lymphomagenesis. In the CESAME study, 
some data regarding disease activity was collated but was not linked to lymphoma risk 
(Beaugerie et al., 2009a). 
15. Other risk factors for lymphoma development 
It is important to recognise a number of other risk factors for lymphoma development which 
are relevant to the IBD population but have not been well studied yet. 
15.1 Pharmacogenomics of thiopurine therapy 
Azathioprine is a pro-drug which is metabolised to 6-mercaptopurine and then to a number 
of further metabolites including 6-thioguanine (6TG) and 6-methylmercaptopurine (6MMP) 
which are associated with myelo- and hepato-toxicity when they accumulate at high levels. 
Important enzymes in this pathway include thiopurine methyl transferase (TPMT) and 
hypoxanthine phosphoribosyltransferase (HPRT). It is recognised that polymorphisms of 
TPMT can influence TPMT activity and hence levels of 6TG and 6MMP. About 1 in 300 
individuals have homozygote TPMT mutations and AZA or 6MP therapy results in very 
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high levels of 6TG causing myelo-toxicity. Those with heterozygote mutations have 
intermediate TPMT activity and dose adjustment of AZA and 6MP may be required. 
Thiopurines are also commonly used drugs for the management of acute lymphoblastic 
leukaemia (ALL) in paediatric patients. Following treatment, these patients have an 
increased risk of subsequently developing secondary myelodysplasia or acute myeloid 
leukaemia but it had been thought that this risk is associated with alkylating agents, 
epipodophyllotoxins or radiation therapy rather than due to AZA. However, Bo et al 
showed that paediatric patients with allelic variations of the TPMT gene (and lower TPMT 
levels) had a higher rate of secondary leukaemias in this setting (Bo et al., 1999). Thiopurines 
result in the incorporation of 6TG, a purine analogue, into lymphocyte DNA which can 
activate DNA repair mechanisms. This introduces the risk of point mutations and 
chromosomal abnormalities during repair processes. It follows that higher levels of 6TG 
may increase this risk further, possibly explaining the link with lymphomagenesis in IBD 
patients treated with thiopurines. 
Disanti et al made an interesting observation in a cohort of IBD patients treated with 6MP 
over a 37 year period. The investigators divided the group of over 600 patients in to those 
who developed a sustained leukopenia of <4.0x109/l for 20 or more days and those who did 
not. They found that there was an increased risk of haematological malignancies in the 
group with sustained leukopenia (p=0.014) (Disanti et al., 2006). 
Although, the TPMT levels were not known in these patients, further investigation in to the 
association between TPMT and lymphoma risk may be intriguing. 
15.2 Radiation exposure 
The use of imaging modalities such as computed tomography and fluoroscopy have been an 
important component for the diagnosis and assessment of IBD but there has been increasing 
concern regarding the cancer risk associated with diagnostic ionising radiation (Brenner and 
Hall, 2007). Much of the risk of medical radiation exposure is extrapolated from studies of 
populations near nuclear explosions and occupational exposure but there is some evidence 
in certain medical settings (Brenner et al., 2003). For example, young patients with scoliosis 
who have had repeated chest x-rays were at increased risk of breast malignancy (Doody et 
al., 2000). 
Recent evidence suggests that CT imaging is being used more frequently in IBD patients, 
particularly those with Crohn’s disease (Newnham et al., 2007, Kroeker et al., 2011). 
Leukaemia is well recognised as a long term consequence of radiation exposure and this risk 
is higher in children (Darby et al., 1992, Shimizu et al., 1990). However, there is little 
evidence to confirm an increased risk of lymphoma in patients exposed to diagnostic 
ionising radiation though the mechanisms of oncogenesis may be similar. There was no 
increased risk of lymphoma seen in patients receiving radiotherapy for uterine cancer nor 
amongst tuberculosis patients with repeated pneumothorax who had an average of 77 chest 
x-rays on follow up (Boice, 1992). A study including 318 NHL patients found no increased 
exposure to diagnostic radiation compared to controls if imaging from the 12 months 
immediately prior to lymphoma diagnosis was excluded. The authors felt that radiological 
procedures within this period were performed to investigate the lymphoma rather than a 
causative factor (Boice et al., 1991). 
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15.3 Vitamin D and sunlight exposure 
Vitamin D deficiency is common amongst IBD patients. Recent studies have shown 
suboptimal levels of Vitamin D in 57 to 78% of recently diagnosed patients with IBD (Leslie 
et al., 2008, Bours et al., 2010). The protective role of Vitamin D has been investigated in a 
number of malignancies including prostate, colon, lung, pancreatic, endometrial, breast and 
even skin cancer (Schwartz and Skinner, 2007). The paracrine and autocrine effects of extra-
renal 25-hydroxy-Vitamin-D3 via the nuclear Vitamin D Receptor (VDR) include regulation 
of cell cycle proliferation, induction of apoptosis and increased cell differentiation 
signalling. 
Recent epidemiologic studies demonstrate a reduction in NHL risk with increased sunlight 
exposure (Armstrong and Kricker, 2007). As sunlight is a major vitamin D source, it has 
been suggested that vitamin D status may mediate this observed association. A recent 
review of the literature could not conclude or dismiss a link between vitamin D insufficiency 
and lymphoma due to confounding findings in a number of studies and the limitations on 
the accuracy of dietary history taking which was the most frequent methodology in these 
studies (Kelly et al., 2009). 
The role of Vitamin D in lymphomagenesis in the IBD population has not been investigated 
and warrants further study. 
16. Summary of findings and application to clinical practice 
This systematic review and the meta-analyses carried out in this chapter have made some 
key findings: 
 There is only a small (if any) increased overall risk of lymphoma in IBD patients. 
 Thiopurine therapy results in a 3 to 4-fold increased risk of lymphoma in IBD patients. 
 The risk of lymphoma with methotrexate therapy cannot be evaluated adequately but 
appears to be low. 
 Treatment with anti-TNF drugs appears to confer an increased risk of lymphoma in IBD 
patients. However, this may reflect previous or concurrent immunomodulator exposure 
rather than the risk of anti-TNFs alone. 
 HSTCL is associated with long term thiopurine therapy. Additionally, anti-TNF therapy 
may increase this risk. 
It is the role of the IBD physician to help patients balance up the risks and benefits of these 
drugs and make the right choice for themselves. Due to the significant morbidity associated 
with IBD, simply avoiding these drugs is frequently not an option. It is mandatory to 
provide clear communication of risks and benefits and to individualise this to the patient 
because lymphoma risk in IBD patients is not uniform nor is the risk of complicated disease. 
A recent study found that patients were more likely to tolerate the risk of adverse events 
due to IBD drug therapy for moderately symptomatic Crohn’s disease than 
gastroenterologists would choose for their patients (Johnson et al., 2010). 
Patient selection is paramount. The risk of most forms of lymphoma appears to be higher in 
males and in older age groups. HSTCL is particularly relevant to men under the age of 35 
years. Special consideration of the risks must be made in these groups. A number of predictors 
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for severe or complicated disease are now being identified which should allow selection of 
patients who are most likely to gain from aggressive treatment (Beaugerie et al., 2006). 
There is ample evidence that immunomodulators and anti-TNF drugs are very effective for 
the treatment of IBD. In a 30 year review, Fraser et al found that there were 64% and 87% 
remission rates at 6 months for patients treated with AZA for Crohn’s disease and ulcerative 
colitis respectively (Fraser et al., 2002). Feagan et al found 65% remission at 40 weeks with 
MTX for Crohn’s disease (Feagan et al., 2000). In the SONIC study, there was 57% remission 
at 1 year for combined AZA and IXB therapy (Colombel et al., 2010). The CHARM study 
and its open label extension, ADHERE, for adalimumab in Crohn’s disease found improved 
fistula healing rates, 57% decreased hospitalisation and improved Work Productivity Scores 
(Panaccione et al., 2010). A Markov model found that the benefits of azathioprine for the 
treatment of Crohn’s disease outweighed the risk of lymphoma but such calculations are 
inherently based on estimations and assumptions (Lewis et al., 2000). 
Additionally, there is evidence that stopping these drugs may be harmful to patients. 
Azathioprine withdrawal leads to relapse within 18 months at 21% vs 8% (p=0.02, NNH=8) 
(Lemann et al., 2005). Methotrexate withdrawal leads to relapse within 40 weeks in 61% vs 
35% (p=0.04, NNH=4) (Feagan et al., 2000). Infliximab withdrawal leads to hospitalisation 
within 1 year in 38% vs 23% (p=0.05, NNH=7) (Rutgeerts et al., 2004). However, the 
CESAME study did suggest that stopping immunomodulator therapy did return the risk of 
lymphoma back to baseline. 
No form of screening is able to predict lymphoma development. Although, the role of 
vitamin D status and TPMT expression on lymphoma risk is intriguing, there is insufficient 
evidence to recommend the routine testing of these parameters to guide patient 
management. Prophylactic use of antivirals in renal transplant recipients has been shown to 
reduce the risk of post-transplant lymphoproliferative disorders by as much as 83% and the 
use of this strategy in IBD patients on immunosuppression is warranted (Funch et al., 2005). 
The morbidity associated with IBD, the efficacy of these drugs and the risks of stopping 
them are important factors in making management decisions with patients. In many 
patients, the benefits will outweigh the risks.  
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